Introduction
============

Deviations of eye movement control are established neurophysiological intermediate phenotypes for psychotic disorders that may be useful for advancing gene discovery in psychiatry.^[@bib1]^ Impairments are seen in a reduced ability to accurately track slowly moving objects with the eyes^[@bib2]^ and to voluntarily suppress a reflexive saccade to a peripheral target on antisaccade tasks.^[@bib3],\ [@bib4]^ Consistent with multiple lines of evidence indicating shared neurobiological alterations and genetic vulnerability across schizophrenia spectrum and psychotic bipolar disorders,^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ comparable eye movement deficits have been demonstrated across these groups in first-episode and chronically ill patients, and in their relatives indicating disturbances in brain systems subserving pursuit initiation and maintenance, and inhibitory control.^[@bib2],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27]^ We recently reported both smooth pursuit impairments and antisaccade inhibition errors in a large cohort of clinically stabilized psychotic disorder cases and their relatives as part of the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium Study.^[@bib28],\ [@bib29],\ [@bib30]^ We found that the initiation of a pursuit movement, which depends on rapid sensorimotor processing, was disturbed in probands and their relatives, while pursuit maintenance, dependent on cognitive predictions of target motion and the most widely used phenotype in prior genetic studies, was mostly impaired in probands.^[@bib29]^ Impaired antisaccade task performance was identified in probands and their relatives, reflecting decreased inhibitory behavioral control.^[@bib28]^ How these intermediate phenotypes are related to genetic variation across the genome has to date not been comprehensively studied.

The first genetic studies of eye movement abnormalities in psychotic disorders reported linkage between pursuit maintenance ability and microsatellite markers on the short arm of chromosome 6 (6p21-23).^[@bib31],\ [@bib32]^ Subsequent genetic studies using eye movement phenotypes have predominantly focused on single nucleotide polymorphisms (SNPs) in candidate genes for schizophrenia disease risk, for example, catechol-*O*-methyltransferase and neuregulin-1.^[@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39]^ Lencer *et al.*^[@bib40]^ reported an association of pursuit-initiation impairments in first-episode psychosis patients with a dopamine D2 receptor gene (*DRD2*), whereas pursuit maintenance was associated to candidate SNPs in metabotropic glutamate receptor 3 protein (*GRM3).* This finding supports a model of different genes being potentially significant for different aspects of eye movement control.

Despite these initial reports, confirmation and larger scale genome-wide association studies (GWAS) in patients with psychosis are lacking. We report herein a GWAS evaluating genetic associations with three eye movement phenotypes representing (1) initial sensorimotor processing (pursuit acceleration), (2) sustained pursuit (maintenance gain) and (3) voluntary inhibitory control (antisaccade error rate) in probands with psychosis and controls from the B-SNIP sample, with additional exploratory pathway analyses to identify biological networks implicated by top findings.

Materials and methods
=====================

Participants
------------

Smooth pursuit and antisaccade measures were assessed in 849 participants (schizophrenia *N*=230, schizoaffective disorder *N*=155, psychotic bipolar disorder *N*=206 and healthy controls *N*=258) of the B-SNIP consortium for whom DNA and genotyping information were available. In depth descriptions of the overall B-SNIP study design, inclusion and exclusion criteria, clinical ratings and eye movement assessments have been previously described.^[@bib28],\ [@bib29],\ [@bib30]^ Diagnoses were made by a consensus process using all available clinical information including the Structured Clinical Interview for DSM IV (SCID)^[@bib41]^ with collateral information from family members when available. Probands were clinically stable and receiving consistent psychopharmacological treatment for at least 1 month ([Table 1;](#tbl1){ref-type="table"} [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).^[@bib42],\ [@bib43],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib47]^

Inclusion criteria for all subjects were (1) age 15--65; (2) WRAT reading score ⩾65;^[@bib42]^ (3) no history of neurologic or systemic disease; (4) minimum of 20/40 visual acuity (with or without correction) and (5) no history of substance abuse within the last month or substance dependence within the last three months according to SCID, and negative urine toxicology (MP On-Site 11: One Step Onsite, ref: 60B02-MPB) on assessment day. Inclusion criteria for control subjects additionally included: (1) no personal or family history (first-degree) of psychotic or bipolar disorder; (2) no history of recurrent depression; and (3) no history of psychosis spectrum personality traits defined as meeting full or within one criteria of a cluster A (psychosis spectrum) Axis-II diagnosis. The study was approved by institutional review boards at each study site and written informed consent was obtained prior to study participation.

Eye movement analyses
---------------------

The eye movement measures ([Table 1](#tbl1){ref-type="table"}) utilized as primary outcome measures in genetic analyses included: (1) initial pursuit acceleration (measure of rapid sensorimotor processing during the first 100ms of pursuit assessed by foveo-petal step-ramp stimuli (18.7°/s);^[@bib29]^ (2) pursuit maintenance gain (accuracy of matching eye to target velocity during sustained pursuit) using a triangular wave task (18.7°/s);^[@bib29]^ and (3) antisaccade error rate defined as the percentage of trials with failed response inhibition from an overlap task,^[@bib28]^ ([Supplementary Material Methods](#sup1){ref-type="supplementary-material"}). Eye movements were acquired with a video-based eye tracker in a darkened room (Eyelink II, SR Research, Ottawa, ON, Canada, sampling rate 500 Hz) with the same testing conditions and hardware used at all B-SNIP sites. Each eye movement measure was standardized using a normative regression approach, transforming data to *z*-scores including age, race and sex as covariates. This was done to remove variance in data related to demographic parameters from all groups in a similar way, and to facilitate comparison of the magnitude of effects across the different groups and pursuit measures. Our previous analyses with the B-SNIP study sample did not identify significant effects of antipsychotic dosing, anticholinergic loading or other medication effects on eye movement measures in these stably treated patients.^[@bib28],\ [@bib29]^ Furthermore, eye movement measures were shown to be relatively independent from general cognitive deficits indicated by BACS scores.^[@bib28],\ [@bib29]^

Genotyping and imputation
-------------------------

Genomic DNA from participants was isolated from whole blood using standard protocols and genotyped by the Broad Institute using the Illumina Infinium PsychChip array. Quality control (QC) procedures were conducted with PLINK v1.9^[@bib48]^ following standardized protocols.^[@bib49]^ Genetic markers deviating from Hardy--Weinberg Equilibrium (*P*\<10E−6), genotype-inferred sex differing from reported sex, or having call rates \<98% were excluded from analyses. We included SNPs that had minor allele frequencies (MAF) ⩾0.01 in case or control groups. Cryptic relatedness was checked with PREST-plus.^[@bib50]^ Samples showing a second degree relationship or greater were excluded resulting in 849 participants available for GWAS.

SNPs passing quality control procedures were used for imputation using HAPI-UR for pre-phasing^[@bib51]^ and IMPUTE2 for imputation^[@bib52]^ using the 1000 Genomes phase 1 data as a reference panel.^[@bib53]^ Poorly imputed SNPs were filtered with the resulting imputed SNPs merged back in with the directly genotyped SNPs from the PsychChip for a total of 4 404 269 SNPs passing filtering criteria used for the analyses described herein.

Genetic ancestry assessments were completed with multi-dimensional scaling (MDS) plots relative to 1000 Genomes Project populations. Race stratified analyses represented a division of the two predominating ancestry components. Analyses of both stratified and whole group analyses utilized the first five principle components of ancestry analyses as covariates.

Genome-wide association analyses approach
-----------------------------------------

We used a mixed-modeling approach as implemented in the Efficient Mixed-Model Association eXpedited (EMMAX)-software package,^[@bib54]^ which uses an identity by state (IBS) relationship matrix, and the first five eigenvectors from principle components analysis (PCA) included as covariates to reliably account for mixed ethnicity populations. Standardized eye movement measures (see above) were modeled as quantitative trait phenotypes in relation to genetic data. Probands and controls were grouped together for primary analyses with all ancestry groups combined. For secondary analyses, the sample was stratified by the top two genetically derived ancestry groups with follow-up studies in the proband only sample. The rationale for grouping cases and controls together in primary analyses was to take advantage of the wider range of phenotypic variance for the examination of genetic contributions to eye movement control.

To account for multiple testing using imputed data, the genome-wide significance threshold was set at 1 x E−08, which is more conservative than the commonly used GWAS significance threshold of 5 x E−08.^[@bib55]^ False discovery rate (FDR) *q*-statistics further adjusting for multiple analyses of phenotypes and race groups were calculated. FDR *q*-values for GWAS significant findings remained \<0.05 with the exception of rs2010148567 in relation to antisaccade response inhibition in African ancestry (AA), where *q*=0.09, all collectively indicating low type I error. We define 'suggestive associations' as *P*-values exceeding 5 x E−7 but not meeting 1 x E−8 GWAS significance. The closest gene was assigned to each SNP using BEDTools closest and RefSeq gene annotations from hg19.^[@bib56]^

Exploratory pathway analyses
----------------------------

We used Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA) to conduct exploratory analyses (using the Core Analysis feature) of genes affiliated (within 15 kb) with the top 200 SNP associations identified through GWAS analyses. Associations in all participants were examined separately for each eye movement measure by merging the top 200 associated SNPs from the two primary ancestry group analyses. The expression quantitative trait loci analyses of top SNPs associated with clinical phenotypes were performed using the Genotype-Tissue Expression GTEx Portal ([www.gtexportal.org/home](http://www.gtexportal.org/home)) and the United Kingdom Brain Expression Consortium (UKBEC, [www.braineac.org](http://www.braineac.org)).

Results
=======

Initial sensorimotor processing
-------------------------------

### GWAS of initial pursuit acceleration in all participants

Across participants, the most robust genome-wide significant association was identified with an isolated SNP in the Importin 8 gene (*IPO8*) at chromosome 12p11.21 ([Table 2](#tbl2){ref-type="table"}). In addition, a number of SNPs in a non-coding RNA gene at chromosome 2p12, and in an intergenic region near the mitogen-activated protein kinase *MAP3K1* gene at chromosome 5q11.2 showed patterns of suggestive association.

### GWAS of initial pursuit acceleration stratified by ancestry

GWAS in participants of predominantly AA (*N*=300) revealed the aforementioned genome-wide significant association with *IPO8*, as well as an additional genome-wide significant association with SNPs in the protocadherin 12 (*PCDH12*) gene at chromosome 5q31.3 ([Figure 1a](#fig1){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). Other polymorphisms with suggestive associations included SNPs \~300 kb upstream of the Neurensin 1 gene (*NRSN1*) in an intergenic region at chromosome 6p22.3 and a SNP in the LIM domain only protein 7 gene (*LMO7*) at chromosome 13q22.2.

In participants of predominantly Caucasian ancestry (CA, *N*=549), initial pursuit acceleration was significantly associated with a SNP representing a missense mutation in *CYB5R3* at chromosome 22q13.2 coding for membrane bound cytochrome B5 reductase 3. In addition, the aforementioned SNPs in a non-coding RNA gene at chromosome 2p12 showed suggestive associations.

### GWAS of initial pursuit acceleration in probands only

Follow-up analyses in probands across ancestries identified the genome-wide significant association with the SNP in *IPO8* that was seen in the whole-study sample, and additionally suggestive association in *LMO7.* Similarly, follow-up analyses in AA probands revealed the genome-wide significant associations with SNPs in *IPO8*, *PCDH12* and *LMO7* ([Table 3](#tbl3){ref-type="table"}). In the sub-sample of CA probands, no genome-wide significant association was observed with initial pursuit acceleration.

Sustained pursuit maintenance
-----------------------------

### GWAS of maintenance gain in all participants

No associations were identified which exceeded our pre-defined threshold for genome-wide significance of 1 × E−8.^[@bib55]^ Suggestive associations with pursuit maintenance gain across all participants were identified with a number of SNPs in or around the src Homology-3 (SH3) domain gene (*SH3GL2*) at chromosome 9p22.2 ([Table 2](#tbl2){ref-type="table"}).

### GWAS of pursuit maintenance gain stratified by ancestry

Suggestive associations with *SH3GL2* were also observed in CA participants only ([Table 2](#tbl2){ref-type="table"}; [Figure 1b](#fig1){ref-type="fig"}). In AA participants, we identified further suggestive associations with pursuit maintenance ability. These included SNPs in *TMPRSS5* at chromosome 11q23.1 encoding a transmembrane serine protease, and in *POP7* at chromosome 7q22.1, which is a protein-coding gene related to gene expression and RNA transport. Very close to this region on chromosome 7, we additionally identified a SNP in *GGYF1,* which encodes a protein believed to act cooperatively with growth factor receptor-bound protein10 (*GRB10*) to regulate tyrosine kinase receptor signaling.

Follow-up analyses in the proband subsample ([Table 3](#tbl3){ref-type="table"}) showed suggestive associations of pursuit maintenance gain with SNPs in *POP7*, *GGYF1* and *TMPRSS5* in the subsample of AA probands but not in CA probands.

GWAS of antisaccade error rates
-------------------------------

GWAS with antisaccade error rate in AA participants identified one GWAS significant SNP and 25 suggestive SNPs in an intergenic region at chromosome 7 ([Table 2](#tbl2){ref-type="table"}; [Figure 1c](#fig1){ref-type="fig"}). However, no further associations with error rate were observed in either the whole sample or proband subsamples considered separately.

More details on top 200 SNPs identified in primary and secondary GWAS are given in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Exploratory pathway analyses
----------------------------

The top 200 SNP associations identified in race stratified GWAS analyses represented 89 distinct genes for initial pursuit acceleration and 103 distinct genes for pursuit maintenance gain ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). A top physiological system category identified for both pursuit phenotypes was nervous system development and function, which was represented by \~19% (*N*=17) of the top genes associated with initial pursuit acceleration and \~22% (*N*=23) of the top genes associated with pursuit maintenance gain (enrichment *P*-value range 4.9−10^−2^--9.8 × 10^−4^). Noting the similarities in pathway relationships identified, the genes comprising these lists were merged (*N*=189 unique genes; *N*=40 genes relevant to the nervous system) and visualized with neural network mapping that highlights the nervous system development and synaptic functioning ([Figure 2](#fig2){ref-type="fig"}). This revealed functions including 'formation of the eye', 'eyelid reflex' and 'electrophysiology of the eye' 'excitatory postsynaptic action potential' as well as 'neurological signs', 'movement disorders' and 'neurodegeneration'. Nineteen of these genes have previously shown evidence for a relationship to psychotic disorders.

Discussion
==========

In this GWAS, we focused on eye movement measures indexing different neurophysiological aspects of eye movement control known to be impaired in psychotic disorders. We identified novel genome-wide significant findings that may promote understanding of psychosis risk and pathophysiology. First, the most significant associations were found for initial sensorimotor processing with *IPO8* at 12p11.21, *PCDH12* at 5q31.3, *CYB5R3* at 22q13.2 and *LMO7* at 13q22.2. These associations were predominantly observed in variants with lower minor frequencies, mostly in AA participants. Second, suggestive associations with sustained pursuit maintenance were observed with protein coding SNPs in and around *SH3GL2* at 9p22.2. Third, significant genome-wide association of behavioral response inhibition was observed with a non-coding region at chromosome 7 in AA participants. All genes for which we found significant associations with referring SNPs are expressed in the brain ([www.gtexportal.org/home](http://www.gtexportal.org/home); [www.braineac.org](http://www.braineac.org)). Those variants exceeding our pre-defined GWAS significance threshold also had low FDR statistics after accounting for multiple comparisons. Finally, exploratory pathway analyses of top associated SNPs identified commonalities between genes related to smooth pursuit measures, which consisted of loci previously associated with brain development, neurophysiology, ocular physiology and schizophrenia risk. These findings provide important new genetic information about what has long been one of the most promising familial phenotypes associated with psychotic disorders.^[@bib1],\ [@bib2],\ [@bib57]^ This said, our findings extend previous reports from large-scale genetic studies showing considerable overlap between schizophrenia spectrum and bipolar disorders.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^

Genetic alterations related to initial sensorimotor processing
--------------------------------------------------------------

The *IPO8* gene, in which we found a missense mutation significantly associated with initial pursuit acceleration, encodes importin 8, which has a key role in nuclear--cytoplasmic transport of proteins including many miRNAs.^[@bib58]^ Importin 8 has also been identified as a component of miRNA-guided regulatory pathways for gene silencing by argonaute proteins, which are ubiquitous proteins found in plants, animals and fungi, leading to mRNA destabilization by transcription repression and translation inhibition.^[@bib59]^ Blocking importin 8 reduces the nuclear concentration of argonaute proteins and may thus attenuate mRNA destabilization.^[@bib59]^ We found this mutation, to date, only identified in those of AA, specifically associated with pursuit acceleration in AA probands.

Other suggestive associations with initial sensorimotor processing in the whole sample included a non-coding RNA gene (chr2p12), and SNPs \~15 kb upstream of *MAP3K1* (chr5q11.2), which encodes a mitogen-activated protein kinase known to regulate apoptosis.^[@bib60]^ There were 52 other SNPs in or around *MAP3K1* including others upstream of the transcription starts site and two missense variants within the coding region, all with association *P*-values ranging from 3.4 × 10^−5^ to 2.2 × 10^−7^. In addition, expression quantitative trait loci analysis of the top associated SNP (rs1862618) revealed a strong correlation with the expression of the SET domain containing 9 gene (*SETD9*) ([www.gtexportal.org/home](http://www.gtexportal.org/home)) at chromosome 5q11.2, coding for a SET7 class of methyltransferase, which methylates H3K4. This correlation exists across multiple tissue types including regions of the brain and skeletal muscle.

Stratified GWAS by ancestry revealed significant genome-wide associations of sensorimotor processing with a synonymous mutation in *Protocadherin 12* (*PCDH12*) in AA participants, primarily driven by effects observed in AA probands. *PCDH12* belongs to a protocadherin gene cluster at chromosome 5q31 that has been previously implicated in schizophrenia and psychosis in non-AA samples.^[@bib61],\ [@bib62]^ *PCDH12* encodes a cellular adhesion molecule that has an important role in cell--cell interactions including axonal guidance and synaptic specificity. The association with initial pursuit acceleration suggests that in psychotic disorders alterations of the cadherin-based adhesive system may alter functional connectivity and coherent information processing in brain systems needed for fast visual information processing.^[@bib63]^ Putative association of *PCDH12* with gyrification asymmetry has also been reported in schizophrenia suggesting its involvement in neurodevelopment and neural network formation.^[@bib64]^ More broadly, our sensorimotor processsing related findings are in line with reports from the B-SNIP sample showing associations between genetic variants of the cadherin family and electroencephalogy abnormalities^[@bib65],\ [@bib66]^ and resting state brain activity seen with imaging studies.^[@bib67]^

Suggestive associations of rapid sensorimotor processing around the Neurensin 1 gene (*NRSN1*, chr6p22.3) were observed in AA participants. *NRSN1* has been suggested to have an important role in the transduction of nerve signals and for neural plasticity. This may explain why *NRSN1* has been previously related to information-processing speed,^[@bib68]^ supporting our finding of a specific association with rapid sensorimotor transformation needed during pursuit initiation.

Another genome-wide association was found for a missense mutation in the *LMO7* gene coding for LIM domain only protein 7 (chr13q22.2) in AA participants in general, and in AA probands specifically at a genome-wide significant level. *LMO7* is involved in protein--protein interactions and transcription, and mutations by alternative splicing in *LMO7* have been related to retinal defects and degeneration,^[@bib69]^ which could explain why we found a SNP in this gene to be associated with rapid retinal error information processing.

Stratified GWAS in CA participants revealed genome-wide significant association of sensorimotor processing with *CYB5R3* (ch22q13.2). Notably, patients with 22q13 deletion syndrome are characterized by autism and schizophrenia-like symptoms.^[@bib70]^ In these patients, loss of *CYB5R3* has been related to impaired language skills.^[@bib70]^

Genetic alterations related to pursuit maintenance
--------------------------------------------------

In contrast to pursuit initiation, sustained pursuit maintenance depends upon an established prediction of target velocity, and thus is more dependent on cognitive function. Here across all participants, we found suggestive associations of sustained pursuit maintenance with a region in the *SH3GL2* gene (chr9p22.2) encoding Endophilin A1.^[@bib71]^ Previous studies in schizophrenia suggest that *SH3GL2* is differentially expressed in gray matter of prefrontal cortex in psychosis patients compared to controls.^[@bib72],\ [@bib73]^ Endophilin A1 is implicated in synaptic vesicle endocytosis involving intracellular signaling, calcium homeostasis and neurotransmitter release.^[@bib73]^ Specifically, Endophilin A1 is suggested to regulate glutamate release in neurons expressing vesicular glutamate transporter 1.^[@bib74]^ This is of interest as we recently found pursuit maintenance being associated with genetic variants in *GRM3*.^[@bib40],\ [@bib75]^

Genetic alterations related to antisaccade response inhibition
--------------------------------------------------------------

SNPs associated with antisaccade performance in AA participants were identified in an intergenic region at chromosome 7 with the closest defined gene being the non-coding RNA LOC101928283, which is \~230 kb away. An expression quantitative trait loci analysis search for the top 10 SNPs within the United Kingdom Brain Expression Consortium (UKBEC) ([www.braineac.org](http://www.braineac.org)) showed significant association with expression of the gene *GPR37* (G protein-coupled receptor 37) within the hippocampus. The encoded protein contains seven transmembrane domains and is found in cell and endoplasmic reticulum membranes. G protein-coupled receptors are involved in translating outside signals into G protein-mediated intracellular effects. A previous GWAS on antisaccade error rate in twins reported suggestive associations with SNPs at chromosome 7 close to the region identified in the present study.^[@bib76]^ The same study also revealed genome-wide significant associations with genes at chromosome 2.^[@bib76]^ Others reported genome-wide linkage of antisaccade error rate with SNPs at chromosome 3p12 from a schizophrenia family study (COGS).^[@bib57]^ Altogether, these findings support the notion that antisaccade error rate may be regarded as a complex polygenic trait.^[@bib76]^

Implications from pathway analyses
----------------------------------

The 200 top SNPs associated with pursuit acceleration and maintenance gain were enriched for genes related to nervous system development pathways including relevant functions such as eye formation, neuronal action potential and movement disorders. Some of these genes have also been identified in previous disease risk association studies for psychotic disorders. Altogether, these findings support the model of smooth pursuit disturbances representing alterations in brain systems contributing to psychosis disease pathology. They are in line with other findings from the B-SNIP sample that revealed brain system changes related to gene clusters indicating physiological pathways involved in brain development, synaptic transmission and ion channel activity.^[@bib67],\ [@bib77]^

### Limitations

Although our findings are novel and potentially heuristically valuable, there are potential limitations. First, although our sample size was large compared to most previous association studies of eye movements in psychosis probands, it is still small for GWAS. To enhance statistical power, we used a combined proband-control sample from the B-SNIP study, which had the benefit of increasing sample size as well as phenotypic variance for genetic association analyses. However, our analyses are not powered to detect smaller genotype--phenotype associations in the individual proband groups. Further research is needed to examine potential disorder-specific effects. Second, some of our more highly associated SNP findings represented those with lower minor allele frequencies (that is, *IPO8, PCDH12, CYB3R5, LMO7*). Special effort was undertaken to assure SNP genotyping quality and phenotyping for these variants, however these associations require validation and replication, especially with respect to the findings in the subgroup of AA participants.

Conclusions
===========

GWAS using eye movement phenotypes offers a promising approach for advancing pathophysiological models and understanding discrete components of complex multifactorial genetic risks for psychosis. We identified regions of interest for further study including some novel findings in addition to suggestive associations that are consistent with prior disease risk studies. Collectively, these findings highlight the importance of genes related to disease risk alongside other unique genetic contributions to eye movement phenotypes associated with psychotic disorders.
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![Manhattan plots from genome-wide association studies (GWAS) stratified for participants of predominantly African ancestry (*N*=300, left side) and participants of predominantly Caucasian ancestry (*N*=549, right side). Results for the three eye movement measures used as phenotypes in GWAS are depicted: (**a**) initial pursuit acceleration, (**b**) pursuit maintenance gain and (**c**) antisaccade error rate. For more details see [Table 2](#tbl2){ref-type="table"}.](tp2017210f1){#fig1}

![Summary of Ingenuity Pathway Analysis (IPA) using genes encoding the top 200 SNPs associated with initial pursuit acceleration and pursuit maintenance within the study population (*N*=849). The functional category nervous system development and function was identified as one of the top five physiological systems represented by these genes. Genes listed from the top have the greatest number of connections to functional categories within the nervous system development category listed in the lower panel. Genes that have shown evidence for a relationship to psychotic disorders are highlighted in red. SNP, single-nucleotide polymorphism.](tp2017210f2){#fig2}

###### Characteristics of probands with psychosis and healthy controls

                                                                       *Psychosis probands,* N=*591*   *Healthy controls,* N=*258*   *Comparison*
  -------------------------------------------------------------------- ------------------------------- ----------------------------- -----------------------------
  Age, mean (s.d.)                                                     35.4 (12.5)                     37 (12.5)                     NS
  Sex (% male)                                                         50%                             46%                           NS
  Predominantly African Ancestry, n (%)[a](#t1-fn2){ref-type="fn"}     224 (38%)                       76 (29.5%)                    *χ*^2^= 5.6; *P*=0.02
  Predominantly Caucasian Ancestry, n (%)[a](#t1-fn2){ref-type="fn"}   367 (62%)                       182 (70.5%)                    
  WRAT 4 Word Reading[b](#t1-fn3){ref-type="fn"}, mean (s.d.)          97.9 (15)                       104.2 (13.7)                  *t*~(842)~=5.8; *P*\<0.001
  BACS[c](#t1-fn4){ref-type="fn"} *z*-score, mean (s.d.)               −1.4 (1.4)                      0.1 (1)                       *t*~(847)~=16.1; *P*\<0.001
  PANSS[d](#t1-fn5){ref-type="fn"} positive, mean (s.d.)               15.9 (5.7)                      NA                            NA
  PANSS[d](#t1-fn5){ref-type="fn"} negative, mean (s.d.)               14.8 (5.5)                      NA                            NA
  PANSS[d](#t1-fn5){ref-type="fn"} total, mean (s.d.)                  62.5 (17.3)                     NA                            NA
  YMRS[e](#t1-fn6){ref-type="fn"}, mean (s.d.)                         6.1 (6.3)                       NA                            NA
  MADRS[f](#t1-fn7){ref-type="fn"}, mean (s.d.)                        10.6 (9.2)                      NA                            NA
  Chlorpromazine equivalents[g](#t1-fn8){ref-type="fn"}, mean (s.d.)   467 mg (434.1)                  NA                            NA
  Antidepressants, n (%)                                               273 (47%)                       NA                            NA
  Mood stabilizer, n (%)                                               287 (49%)                       NA                            NA
                                                                                                                                      
  *Smooth pursuit and antisaccade performance*                                                                                       
   Initial pursuit acceleration, mean (s.d.)                           60.7°/s^2^ (34)                 80.5°/s^2^ (35.7)             *t*~(847)~=8.56; *P*\<0.001
   Pursuit maintenance gain, mean (s.d.)                               0.86 (0.17)                     0.93 (0.1)                    *t*~(835)~=7.64; *P*\<0.001
   Antisaccade error rate, mean (s.d.)                                 39.1% (26)                      18.5% (13)                    *t*~(137)~=4.34; *P*\<0.001

Abbreviations: NS, not significant; NA, not applicable.

According to principal component analyses (PCA).

Wide Range Achievement Test 4th---Edition: Reading.^[@bib42]^

Brief Assessment of Cognition in Schizophrenia,^[@bib43]^ *z*-scores are given relative to test norms.

Positive and Negative Symptom Scale.^[@bib44]^

Montgomery Asberg Depression Rating Scale.^[@bib45]^

Young Mania Rating Scale.[@bib46]

According to Andreason *et al.*^[@bib47]^

###### Top SNPs associated with eye movement measures in the combined proband-control sample and in subsets defined by ancestry

  *Cohort*                         *Gene*             *SNP ID*          *Location*              *SNP type*       *Description*               P*-value*
  -------------------------------- ------------------ ----------------- ----------------------- ---------------- --------------------------- --------------
  *Initial pursuit acceleration*                                                                                                             
  * *Combined ancestry             **IPO8**           **rs142754383**   **Chr12:30814184**      **Missense**     **c.1772A\>G; K591R**       **7.8E−11**
                                   MAP3K1             rs1862618         Chr5:56096315           Intergenic       g.56096315G\>C              2.15E−07
                                   LOC101927967       rs12617011        Chr2:77992269           Intergenic       g.77992269C\>T              2.56E−07
                                   LOC101927967       rs2129493         Chr2:77990458           Intergenic       g.77990458A\>T              2.9E−07
                                   LOC101927967       rs4853338         Chr2:77995848           Intergenic       g.77995848G\>A              3.68E−07
                                   LOC101927967       rs1872787         Chr2:77990824           Intergenic       g.77990824A\>G              3.74E−07
                                   LOC101927967       rs192238154       Chr2:77985105           Intergenic       g.77985105G\>A              4.90E−07
                                   LOC101927967       rs2861081         Chr2:77991268           Intergenic       g.77991268C\>T              4.91E−07
                                                                                                                                              
   African ancestry                **IPO8**           **rs142754383**   **Chr12:30814184**      **Missense**     **c.1772A\>G; K591R**       **1.61E−10**
                                   **PCDH12**         **rs105633**      **Chr5:141325249**      **Synonymous**   **c.3252A\>G; P1084P**      **1.61E−10**
                                   NRSN1              rs144819560       Chr6:23818448           Intergenic       g.23818448A\>G              5.35E−08
                                   NRSN1              rs76257869        Chr6:23755905           Intergenic       g.23755905T\>C              5.44E−08
                                   LMO7               rs76082815        Chr13:76395342          Missense         c.2393C\>T; P798L           7.34E−08
                                   SPAG16             rs72952023        Chr2:215177990          Intronic         c.1721-96874C\>T            8.48E−08
                                   SPAG16             rs72952024        Chr2:215178086          Intronic         c.1721-96778G\>A            1.02E−07
                                   LOC105372897       rs115777110       Chr1:209109556          Intergenic       g.209109556T\>C             1.14E−07
                                   CABLES1            rs4800149         Chr18:20744254          Intronic         c.846-24548C\>A             1.48E−07
                                   PLCB4              rs2299682         Chr20:9429344           Intronic         c.2844+4454A\>G             4.27E−07
                                                                                                                                              
   Caucasian ancestry              CYB5R3             rs61743746        Chr22:43015787          Missense         c.997G\>A; V333I            7.68E−10
                                   LOC101927967       rs74261103        Chr2:77986915           Intergenic       g.77986915A\>G              2.75E−07
                                   LOC101927967       rs13386612        Chr2:77987549           Intergenic       g.77987549 C\>A             4.08E−07
                                   LOC101927967       rs10181488        Chr2:77987909           Intergenic       g.77987909T\>G              4.08E−07
                                                                                                                                              
  *Pursuit maintenance gain*                                                                                                                 
   Combined ancestry               SH3GL2             rs78314758        Chr9:17695593           Intronic         c.46-51471G\>A              3.21E−08
                                   ACTL7A             rs56031956        Chr9:111625629          Missense         c.1027C\>G; L343V           1.36E−07
                                   SH3GL2             rs145586720       Chr9:17693570-71        Intronic         c.46-53485_del-CA           1.40E−07
                                   SH3GL2             rs77484701        Chr9:17653768           Intronic         c.45+74483G\>A              2.00E−07
                                   TTC16              rs77630455        Chr9:130487157          Missense         c.1240T\>G; F414V           3.71E−07
                                   SH3GL2             rs16935877        Chr9:17687749           Intronic         c.46-59315G\>A              3.73E−07
                                   UXS1               rs6738485         Chr2:106809960          Intronic         c.94+644G\>A                3.79E−07
                                                                                                                                              
   African ancestry                TMPRSS5            rs7939917         Chr11:113568096         Missense         c.373G\>A, V125M            5.4E−08
                                   GIGYF1             rs221798          Chr7:100287495          Upstream         g.100287495C\>G             6.89E−08
                                   POP7               rs221774          Chr7:100298984          Upstream         g.100298984A\>G             6.96E−08
                                   POP7               rs221778          Chr7:100298024          Upstream         g.100298024A\>G             7.07E−08
                                   MIR924HG           rs150177813       Chr18:37153343          Non-coding       g.37153343T\>C              1.61E−07
                                   EPO                rs506597          Chr7:100313420          Intergenic       g.100313420A\>G             3.02E−07
                                   C11orf21           rs188839109       Chr11:2323089           Start lost       c.3G\>A; M1I                3.18E−07
                                   LOC730100          rs79125412        Chr2:52510092           Intronic         g.52510092G\>T              3.49E−07
                                   CCDC102B           rs12052005        Chr18:66499548          Intronic         c.-15-4438G\>T              4.07E−07
                                   POP7               rs2432929         Chr7:100299028          Upstream         g.100299028C\>T             4.17E−07
                                   LINC01098          rs56196471        Chr4:179563815          Intergenic       g.179563815G\>A             4.19E−07
                                   POP7               rs221770          Chr7:100302094          Upstream         g.100302094A\>T             4.45E−07
                                   LIFR               rs3729734         Chr5:38527308           Missense         c.346C\>T; H116Y            4.46E−07
                                                                                                                                              
  ** **Caucasian ancestry          AKR1C8P            rs139515701       Chr10:5219539           Intronic         c.93+7436C\>G               1.85E−07
                                   SLC35B3            rs15300           Chr6:8413412            3′UTR            c.\*370T\>C                 2.37E−07
                                   SH3GL2             rs16935877        Chr9:17687749           Intronic         c.46-59315G\>A              2.38E−07
                                   KSR2               rs61945387        Chr12:118359414         Intronic         c.180+46467T\>C             2.73E−07
                                   SH3GL2             rs145586720       Chr9:17693570-71        Intronic         c.46-53485_del-CA           3.32E−07
                                   PTPRD              rs12340173        Chr9:8346473            Intronic         c.4662-4495T\>G             4.15E−07
                                   LOC100506207       rs9505461         Chr6:8495128            Non-coding       g.8495128C\>G               4.55E−07
                                                                                                                                              
  *Antisaccade error rate*                                                                                                                   
  ** **African ancestry            **LOC101928283**   **rs201048567**   **Chr7:125255085-86**   **Intergenic**   **g.125255085-86_del-CA**   **6.45E−09**
                                   LOC101928283       rs34743817        Chr7:125255087-88       Intergenic       g.125255087-88_del-AT       1.06E−08
                                   LOC101928283       rs7781657         Chr7:125255150          Intergenic       g.125255150G\>A             1.06E−08
                                   LOC101928283       rs12690985        Chr7:125258854          Intergenic       g.125258854G\>T             9.25E−08
                                   LOC101928283       rs12706670        Chr7:125258919          Intergenic       g.125258919T\>G             9.25E−08
                                   LOC101928283       rs12706671        Chr7:125259006          Intergenic       g.125259006A\>C             9.25E−08
                                   LOC101928283       rs2402782         Chr7:125259452          Intergenic       g.125259452A\>G             9.25E−08
                                   LOC101928283       rs1419699         Chr7:125261928          Intergenic       g.125261928G\>T             9.25E−08
                                   LOC101928283       rs1579225         Chr7:125256488          Intergenic       g.125256488A\>G             9.79E−08
                                   LOC101928283       rs1579226         Chr7:125256536          Intergenic       g.125256536G\>A             9.79E−08
                                   LOC101928283       rs7785560         Chr7:125255700          Intergenic       g.125255700A\>G             1.06E−07
                                   LOC101928283       rs7785979         Chr7:125255865          Intergenic       g.125255865C\>T             1.06E−07
                                   LOC101928283       rs1579224         Chr7:125256395          Intergenic       g.125256395C\>A             1.06E−07
                                   LOC101928283       rs6957945         Chr7:125256870          Intergenic       g.125256870A\>T             1.06E−07
                                   LOC101928283       rs4634578         Chr7:125257232          Intergenic       g.125257232T\>G             1.06E−07
                                   LOC101928283       rs10227132        Chr7:125258712          Intergenic       g.125258712G\>A             1.06E−07
                                   LOC101928283       rs6467020         Chr7:125262711          Intergenic       g.125262711A\>G             1.15E−07
                                   LOC101928283       rs6467021         Chr7:125262864          Intergenic       g.125262864G\>A             1.15E−07
                                   LOC101928283       rs10234626        Chr7:125266178          Intergenic       g.125266178G\>A             1.27E−07
                                   LOC101928283       rs10954078        Chr7:125265983          Intergenic       g.125265983G\>A             1.37E−07
                                   LOC101928283       rs6958258         Chr7:125257092          Intergenic       g.125257092A\>G             1.64E−07
                                   LOC101928283       rs4731257         Chr7:125266497          Intergenic       g.125266497A\>G             2.32E−07
                                   LOC101928283       rs1579222         Chr7:125251771          Intergenic       g.125251771A\>T             2.59E−07
                                   LOC101928283       rs6962819         Chr7:125257347          Intergenic       g.125257347G\>A             2.80E−07

Listed are associations of *P*\<5 × E−07, genome-wide significant associations (*P*\<1 × E−08) are highlighted in bold.

###### Top SNPs associated with eye movement measures across all probands and in subsets of probands defined by ancestry

  *Cohort*                         *Symbol*       *Assay ID*        *Location*           *SNP type*       *Description*            P*-value*
  -------------------------------- -------------- ----------------- -------------------- ---------------- ------------------------ --------------
  *Initial pursuit acceleration*                                                                                                   
  * *Combined ancestry             IPO8           rs142754383       Chr12:30814184       Missense         c.1772A\>G; K591R        9.0E−13
                                   LMO7           rs76082815        Chr13:76395342       Missense         c.2393C\>T; P798L        3.99E−08
                                   SLC25A51P1     rs9354352         Chr6:66696272        Intergenic       g.66696272T\>C           1.66E−07
                                   SLC25A51P1     rs7766730         Chr6:66697003        Intergenic       g.66697003C\>A           3.67E−07
                                                                                                                                    
   African ancestry                **PCDH12**     **rs105633**      **Chr5:141325249**   **Synonymous**   **c.3252A\>G; P1084P**   **7.60E−12**
                                   **IPO8**       **rs142754383**   **Chr12:30814184**   **Missense**     **c.1772A\>G; K591R**    **7.60E−12**
                                   **LMO7**       **rs76082815**    **Chr13:76395342**   **Missense**     **c.2393C\>T; P798L**    **6.37E−09**
                                   STX2           rs137928907       Chr12:131311749      Missense         c.94T\>G; F32V           2.33E−08
                                   RPN2           rs74417947        Chr20:35810114       Intronic         c.13+2342G\>A            2.33E−08
                                   LOC105372897   rs115777110       Chr1:209109556       Intergenic       g.209109556T\>C          2.33E−08
                                   ZNF740         rs74796725        Chr12:53581383       3′UTR            c.\*9G\>T                2.33E−08
                                   CABLES1        rs4800149         Chr18:20744254       Intronic         c.846-24548C\>A          7.01E−08
                                   LTN1           rs57646126        Chr21:30331935       Missense         c.2438C\>T; A813V        8.0E−08
                                   PLCB4          rs2299682         Chr20:9429344        Intronic         c.2844+4454A\>G          9.44E−08
                                   SLC8A1-AS1     rs138449918       Chr2:40163950-1      Intronic         n.132+13922-3 del AT     1.07E−07
                                   ARL4C          rs13001243        Chr2:235214648       Intergenic       g.235214648G\>A          2.06E−07
                                   ARL4C          rs35862416        Chr2:235212881       Intergenic       g.235212881G\>A          2.06E−07
                                   ARL4C          rs36018891        Chr2:235214867       Intergenic       g.235214867T\>C          2.06E−07
                                   ARL4C          rs71423631        Chr2:235213999       Intergenic       g.235213999A\>G          2.06E−07
                                   MIR572         rs77867520        Chr4:11187849        Intergenic       g.11187849C\>T           2.09E−07
                                   ARL4C          rs34115968        Chr2:235213474       Intergenic       g.235213474C\>T          2.17E−07
                                   LOC285889      rs62482377        Chr7:156043640       Intergenic       g.156043640G\>C          2.87E−07
                                   LOC285889      rs11523169        Chr7:156051554       Intergenic       g.156051554C\>G          3.02E−07
                                   LOC285889      rs11523673        Chr7:156051784       Intergenic       g.156051784T\>A          3.02E−07
                                   LOC285889      rs12698389        Chr7:156056275       Intergenic       g.156056275G\>A          3.02E−07
                                   ARHGEF10L      rs146330533       Chr1:17996466        Intronic         c.2118+5376G\>A          3.49E−07
                                   CABLES1        rs28625207        Chr18:20746672       Intronic         c.846-22130A\>G          3.72E−07
                                   CCDC175        rs34486957        Chr14:60045597       5′ upstream      g.60045597C\>T           4.27E−07
                                   LINC00615      rs75062117        Chr12:91277332       Intergenic       g.91277332G\>A           4.89E−07
                                                                                                                                    
   Caucasian ancestry              MIR5007        rs2997119         Chr13:56393900       Intergenic       g.56393900A\>G           3.3E−07
                                                                                                                                    
  *Pursuit maintenance gain*                                                                                                       
   Combined ancestry               UXS1           rs6738485         Chr2:106809960       Intronic         c.94+644G\>A             3.32E−07
                                   ACTL7A         rs56031956        Chr9:111625629       Missense         c.1027C\>G; L343V        3.78E−07
                                                                                                                                    
   African ancestry                POP7           rs221774          Chr7:100298984       Upstream         g.100298984A\>G          1.01E−08
                                   GIGYF1         rs221798          Chr7:100287495       Upstream         g.100287495C\>G          1.01E−08
                                   POP7           rs221778          Chr7:100298024       Upstream         g.100298024A\>G          1.15E−08
                                   C11orf21       rs188839109       Chr11:2323089        Start lost       c.3G\>A; M1I             2.33E−08
                                   LINC01098      rs56196471        Chr4:179563815       Intergenic       g.179563815G\>A          8.68E−08
                                   EPO            rs506597          Chr7:100313420       Intergenic       g.100313420A\>G          1.01E−07
                                   POP7           rs2432929         Chr7:100299028       Upstream         g.100299028C\>T          1.26E−07
                                   POP7           rs221770          Chr7:100302094       Upstream         g.100302094A\>T          1.38E−07
                                   CCDC102B       rs12052005        Chr18:66499548       Intronic         c.-15-4438G\>T           2.62E−07
                                   LOC100506422   rs2571521         Chr9:26133808        Intergenic       g.26133808C\>G           3.08E−07
                                   TMPRSS5        rs7939917         Chr11:113568096      Missense         c.373G\>A, V125M         3.96E−07
                                                                                                                                    
   Caucasian ancestry              KSR2           rs61945387        Chr12:118359414      Intronic         c.180+46467T\>C          2.32E−07
                                   KSR2           rs17511946        Chr12:118353809      Intronic         c.180+52072T\>C          4.20E−07
                                                                                                                                    
  *Antisaccade error rate*                                                                                                         
   African ancestry                LOC101929645   rs679895          Chr5:29091685        Intergenic       g.29091685C\>T           2.24E−07
                                   LOC101929645   rs251058          Chr5:29093971        Intergenic       g.29093971T\>A           2.25E−07
                                   ATP6V1E2       rs11125080        Chr2:46732405        Intronic         n.776-14435C\>T          2.37E−07
                                   LOC101928283   rs201048567       Chr7:125255085-86    Intergenic       g.125255085-86_del-CA    2.45E−07
                                   LOC101929645   rs185168          Chr5:29093926        Intergenic       g.29093926C\>T           2.49E−07
                                   LOC101928283   rs34743817        Chr7:125255087-88    Intergenic       g.125255087-88_del-AT    4.33E−07
                                   LOC101928283   rs7781657         Chr7:125255150       Intergenic       g.125255150G\>A          4.33E−07
                                   LOC101929645   rs160309          Chr5:29100077        Intergenic       g.29100077T\>A           4.33E−07
                                   LOC101929645   rs168759          Chr5:29095301        Intergenic       g.29095301G\>A           4.33E−07
                                   LOC101929645   rs170138          Chr5:29098460        Intergenic       g.29098460A\>T           4.33E−07
                                   LOC101929645   rs193967          Chr5:29095648        Intergenic       g.29095648G\>A           4.33E−07
                                   LOC101929645   rs309675          Chr5:29107238        Intergenic       g.29107238G\>T           4.33E−07
                                   LOC101929660   rs309677          Chr5:29109039        Intergenic       g.29109039T\>G           4.33E−07
                                   LOC101929660   rs309678          Chr5:29109286        Intergenic       g.29109286G\>C           4.33E−07
                                   LOC101929660   rs160312          Chr5:29112050        Intergenic       g.29112050T\>C           4.42E−07

Abbreviation: SNP, single-nucleotide polymorphism. Listed are associations of *P*\<5 × E−07, genome-wide significant associations (*P*\<1 × E−08) are highlighted in bold.
